Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; poloxamer; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 6000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. eferas is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,eferas is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; poloxamer; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; purified talc; macrogol 6000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. eferas is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective.,eferas is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - suvorexant, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; copovidone; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - belsomra is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. following initiation of treatment, continuation should be re-evaluated after 3 months [see pharmacodynamic properties, clinical trials and adverse effects (undesirable effects) for clinical trial durations].

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - suvorexant, quantity: 15 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; copovidone; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - belsomra is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance.,following initiation of treatment, continuation should be re-evaluated after 3 months [see pharmacodynamic properties, clinical trials and adverse effects (undesirable effects) for clinical trial durations].

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet - excipient ingredients: magnesium stearate; silicon dioxide; calcium phosphate; microcrystalline cellulose; sodium starch glycollate type a - hypertension,alkem amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of alkem amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,angina,alkem amlodipine is indicated for the first line treatment of chronic stable angina. alkem amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amlodipine besilate, quantity: 6.93 mg (equivalent: amlodipine, qty 5 mg) - tablet - excipient ingredients: calcium phosphate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; silicon dioxide - hypertension,alkem amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of alkem amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,angina,alkem amlodipine is indicated for the first line treatment of chronic stable angina. alkem amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amlodipine besilate, quantity: 6.93 mg (equivalent: amlodipine, qty 5 mg) - tablet - excipient ingredients: calcium phosphate; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; silicon dioxide - hypertension alkem amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of alkem amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor angina alkem amlodipine is indicated for the first line treatment of chronic stable angina. alkem amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet - excipient ingredients: magnesium stearate; silicon dioxide; calcium phosphate; microcrystalline cellulose; sodium starch glycollate type a - hypertension alkem amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of alkem amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina alkem amlodipine is indicated for the first line treatment of chronic stable angina. alkem amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.867 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: mannitol; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; sodium starch glycollate - hypertension: amlo 10 tablets are indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoreceptor blocking agent or an angiotensin-converting enzyme inhibitor. angina: amlo 10 tablets are indicated for the first line treatment of chronic stable angina. amlo 10 tablets may be used alone, as monotherapy or in combination with other antianginal drugs.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - minocycline hydrochloride dihydrate, quantity: 54 mg (equivalent: minocycline, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; sodium starch glycollate; sodium lauryl sulfate; titanium dioxide; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 400 - infections due to the following organisms, provided that they have been shown by bacteriological testing to be susceptible to minocycline: escherichia coli; enterobacter aerogenes; haemophilus influenzae; klebsiella and proteus. in addition, infections due to streptococcus pyogenes (group a beta-haemolytic) and streptococcus faecalis, however, because a large proportion of these organisms are resistant to tetracyclines, minocycline should be used only if the organisms have definitely been shown to be sensitive. tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. minocycline may be used in the treatment of tetracycline resistant acne.